Novo partners with Merrion over Insulin analogs

15 December 2008

Denmark's Novo Nordisk has entered into a deal to co-develop and commercialize oral formulations of its Insulin analogues using Irish firm Merrion Pharmaceuticals' GIPET technology. Under the agreement, Merrion will receive up to $58.0 million based on achievement of certain milestones, as well as royalties on sales. Novo will pay for the development and commercialization of the product candidates and Merrion will fund the first clinical batches.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight